We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CR Digital Mammography System First to Have Both FDA Clearance and EUREF Certification

By HospiMedica International staff writers
Posted on 01 Feb 2012
A new computed radiography (CR) mammography digitizer that offers consistent, very high image quality is now available in the US market.

Agfa HealthCare (Mortsel, Belgium) announced that it has received FDA clearance to market its DX-M digitizer with needle-based detectors in the United States. More...
This next-generation CR solution is the only CR digital mammography solution with both US Food and Drug Administration (FDA) clearance and EUREF (European Reference Organization for Quality Assured Breast Screening and Diagnostic Services) certification.

The DX-M with needle-based detectors provides excellent image quality with high detective quantum efficiency (DQE). With its novel five-cassette drop-and-go buffer for high throughput, it also supports a smoother workflow.

The DX-M can be used as a centralized or decentralized digitizer in the radiography department, supporting general radiography as well as digital mammography. As the reader unit can also be used with general radiography detectors, the DX-M is suitable for healthcare operations with a tight budget that wish to achieve high image quality in their X-ray imaging. The DX-M comes with Agfa HealthCare’s Musica2 advanced image processing software for consistently high image quality and enhanced details.

The phosphor needle-based DX-M is a robust system at a reduced total cost of ownership. Furthermore, this allows it to be used in more physically demanding environments, such as mobile mammography screening vans. In addition to the FDA clearance, the DX-M has also passed the rigorous physicotechnical and clinical tests for EUREF, and received EUREF certification.

“We are pleased and proud that the DX-M is the only CR digital mammography solution to have achieved both FDA clearance and EUREF certification,” commented Dirk Debusscher, vice president imaging at Agfa HealthCare. “We remain committed to offering the highest standards based on needle detectors in our CR solutions. We already have more than 3,000 digital mammography installations around the world, and more than 2,000 needle detector-based installations.”

The DX-M is a major part of Agfa HealthCare’s digital mammography solution, which also includes the Impax for Breast Imaging diagnostic workstation and Drystar imagers. By crossing imaging and healthcare information technology (IT) boundaries, it offers a fully integrated system designed for the specific needs of breast imaging departments.

Related Links:

Agfa HealthCare




Gold Member
12-Channel ECG
CM1200B
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Fetal Monitor
BT-380
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.